Circulating tumor cells in small-cell lung cancer
| Autor: | Gerald S. M. A. Kerner, A.M. van den Berg, Hendrika Boezen, Arjan G.J. Tibbe, Leon W.M.M. Terstappen, Frank A.E. Kruyt, Thijo J N Hiltermann, Wim Timens, Milind Pore, J.H. Schouwink, W.J.A. Wijnands, Harry J.M. Groen, Jeroen J W Liesker, H. Tissing |
|---|---|
| Přispěvatelé: | Stem Cell Aging Leukemia and Lymphoma (SALL), Translational Immunology Groningen (TRIGR), Groningen Research Institute for Asthma and COPD (GRIAC), Life Course Epidemiology (LCE), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Faculty of Science and Technology, Medical Cell Biophysics |
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Male medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Platinum Compounds PROGRESSION IR-84085 circulating tumor cells CLASSIFICATION Circulating tumor cell METIS-289041 METASTATIC BREAST-CANCER Internal medicine Biomarkers Tumor small-cell lung cancer Medicine Humans Extensive stage Prospective Studies treatment prediction 7TH EDITION Prospective cohort study Lung cancer Aged Aged 80 and over Chemotherapy business.industry Hematology Middle Aged CHEMOTHERAPY medicine.disease Neoplastic Cells Circulating Metastatic breast cancer Chemotherapy regimen Small Cell Lung Carcinoma Treatment Outcome DIFFERENTIATION SURVIVAL Female Non small cell prognosis CLINICAL-PRACTICE GUIDELINES business STAGING PROJECT PROPOSALS |
| Zdroj: | Annals of Oncology, 23(11), 2937-2942. Oxford University Press Annals of oncology, 23(11), 2937-2942. Oxford University Press |
| ISSN: | 0923-7534 |
| Popis: | BACKGROUND: Initial response of small-cell lung cancer (SCLC) to chemotherapy is high, and recurrences occur frequently, leading to early death. This study investigated the prognostic value of circulating tumor cells (CTCs) in patients with SCLC and whether changes in CTCs can predict response to chemotherapy.PATIENTS AND METHODS: In this multicenter prospective study, blood samples for CTC analysis were obtained from 59 patients with SCLC before, after one cycle, and at the end of chemotherapy. CTCs were measured using CellSearch® systems.RESULTS: At baseline, lower numbers of CTCs were observed for 21 patients with limited SCLC (median = 6, range 0-220) compared with 38 patients with extensive stage (median = 63, range 0-14 040). Lack of measurable CTCs (27% of patients) was associated with prolonged survival (HR 3.4; P ≤ 0.001). CTCs decreased after one cycle of chemotherapy; this decrease was not associated with tumor response after four cycles of chemotherapy. CTC count after the first cycle of chemotherapy was the strongest predictor for overall survival (HR 5.7; 95% CI 1.7-18.9; P = 0.004).CONCLUSION: Absolute CTCs after one cycle of chemotherapy in patients with SCLC is the strongest predictor for response on chemotherapy and survival. Patients with low initial CTC numbers lived longer than those with higher CTCs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|